Ibrahim Helmy, MD
Clinical Cardiac Electrophysiology · Inglewood, CANPI 1598795247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in CA, where the typical reported total is $26,911.
Across 234 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Bayer$494
- Pfizer$468
- Amgen$440
- Boehringer Ingelheim$420
- Merck$329
- plus $2K from 20 others
Across 2 payments — averaging $6475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
What the payments were for
- Food & beverage$4,88298%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 78 | $1,072 |
| Bayer | 20 | $494 |
| Pfizer | 21 | $468 |
| Amgen | 17 | $440 |
| Boehringer Ingelheim | 16 | $420 |
| Merck | 15 | $329 |
| Johnson & Johnson | 11 | $294 |
| E.r. Squibb & Sons, L.L.C. | 9 | $191 |
| Astellas Pharma US Inc | 6 | $176 |
| Abbott | 4 | $151 |
| Lexicon Pharmaceuticals, Inc. | 6 | $142 |
| AstraZeneca | 7 | $141 |
| Scpharmaceuticals Inc. | 5 | $114 |
| Bridgebio Pharma, Inc. | 2 | $102 |
| Regeneron Healthcare Solutions, Inc. | 5 | $98 |
| Impulse Dynamics (USA) Inc. | 1 | $61 |
| Boston Scientific | 2 | $53 |
| Kestra Medical Technology Services, Inc. | 1 | $41 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| Chiesi USA, Inc. | 1 | $28 |
| Heartflow, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Coala Life Inc | 1 | $19 |
| GSK | 1 | $19 |
| Novo Nordisk | 1 | $18 |
How this compares
$4,971 in reported general payments places this provider in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $109,337 |
| EntrestoSacubitril/Valsartan | 65 | $64,449 |
| XareltoRivaroxaban | 29 | $40,544 |
| Repatha SureclickEvolocumab | 43 | $35,963 |
| JardianceEmpagliflozin | 11 | $13,672 |
| KerendiaFinerenone | 11 | $10,401 |
| Valsartan | 219 | $8,193 |
| Doxazosin Mesylate | 127 | $3,400 |
| Rosuvastatin Calcium | 227 | $2,935 |
| Lisinopril | 124 | $1,599 |
| Metoprolol Succinate | 77 | $1,179 |
| Atorvastatin Calcium | 137 | $1,149 |
| Amlodipine Besylate | 158 | $976 |
| Ezetimibe | 34 | $958 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $468 | $109,337114 claims |
| NovartisEntresto | $1,072 | $64,44965 claims |
| Johnson & JohnsonXarelto | $294 | $40,54429 claims |
| Boehringer IngelheimJardiance | $420 | $13,67211 claims |
| BayerKerendia | $494 | $10,40111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Inglewood
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
- Rajesh BankerNewport Beach$538K
- Rahul DoshiLos Angeles$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.